KATHLEEN K SCHOEMAKER
CIK 1207789 · last filed 2015-07-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$324.65M
Companies
21
Total Filings
58
Lifetime Open-Market Net
$110.83M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GKOS | 10%+ Owner | 876,083 | $162.06 | $141.98M | $0 | 1 | 2015-07-01 |
| LIFE | 10%+ Owner | 958 | $19.66 | $18.8K | $0 | 1 | 2015-05-12 |
| MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | 10%+ Owner | 514,286 | $0.55 | $282.9K | $20.15M | 1 | 2014-08-07 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 33,890 | — | — | $0 | 1 | 2014-03-17 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | 10%+ Owner | 13,004 | $38.22 | $497.0K | $0 | 1 | 2014-02-04 |
| TNDM | 10%+ Owner | 318,906 | $18.64 | $5.95M | $0 | 1 | 2013-11-19 |
| VCYT | 10%+ Owner | 3,063,294 | $55.54 | $170.14M | $0 | 1 | 2013-11-04 |
| Evoke Pharma Inc (OMED) Delisted | 10%+ Owner | 5,250 | — | — | $0 | 1 | 2013-09-30 |
| Tobira Therapeutics, Inc. (RGDO) Delisted | 10%+ Owner | 513 | — | — | $3.00M | 1 | 2013-08-28 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | 10%+ Owner | 1,897,336 | — | — | $8.00M | 1 | 2013-07-16 |
| ESPR | 10%+ Owner | 2,066,935 | $3.18 | $6.57M | $4.00M | 1 | 2013-07-02 |
| Clovis Oncology, Inc. (CLVS) Delisted | 10%+ Owner | 79,422 | $0.08 | $6.4K | $10.86M | 2 | 2013-06-05 |
| CADENCE PHARMACEUTICALS INC (CADX) Delisted | 10%+ Owner | 88,011 | — | — | $13.44M | 6 | 2013-03-21 |
| ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | 10%+ Owner | 159,896 | — | — | $0 | 3 | 2013-01-18 |
| Durata Therapeutics, Inc. (DRTX) Delisted | 10%+ Owner | 22,306 | — | — | $7.06M | 1 | 2012-07-24 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | 10%+ Owner | 5,970 | — | — | $25.33M | 15 | 2011-12-22 |
| ZOGENIX, INC. (ZGNX) Delisted | 10%+ Owner | 21,156 | $26.68 | $564.4K | $16.40M | 2 | 2011-09-20 |
| ALIMERA SCIENCES INC (ALIM) Delisted | 10%+ Owner | 1,258 | $5.54 | $7.0K | $4.10M | 2 | 2011-06-03 |
| Paratek Pharmaceuticals, Inc. (NOVC) Delisted | 10%+ Owner | 3,115,960 | — | — | -$514.6K | 3 | 2009-01-30 |
| Volcano Corp (VOLC) Delisted | 10%+ Owner | 1,898,427 | — | — | -$985.0K | 8 | 2008-07-18 |
| SENORX INC (SENO) Delisted | 10%+ Owner | 24,665 | — | — | $0 | 1 | 2007-04-03 |
Recent Filings · Page 4 of 6
58 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2009-12-21 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +138,100 | $1.04M | EDGAR |
| 2009-12-21 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +138,100 | $1.04M | EDGAR |
| 2009-11-25 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +50,000 | $337.5K | EDGAR |
| 2009-11-24 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +400,000 | $2.77M | EDGAR |
| 2009-11-16 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +62,000 | $427.8K | EDGAR |
| 2009-11-12 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +138,000 | $956.3K | EDGAR |
| 2009-08-19 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +13,784 | $106.6K | EDGAR |
| 2009-08-18 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +89,426 | $692.7K | EDGAR |
| 2009-08-14 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +413,000 | $3.30M | EDGAR |
| 2009-08-13 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +104,300 | $792.7K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.